AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Partnering to unlock the true potential of cannabis in medical care
Innoplexus AG announces the appointment of Christian Bigatà Joseph as Chief Financial Officer (CFO) and Dr. Katharina Schreeb as Chief Medical Officer (CMO)
Eschborn, 11.03.2020 – The Supervisory Board of Innoplexus AG has appointed Christian Bigatà Joseph (45) as CFO, effective as of February 1, 2020. Christian has more than 20 years of Finance expertise, the largest part spent in management positions in Tech and Data companies. Amongst other mandates, he has served as CFO and Member of the Board at GfK SE, one of the world’s largest data specialist and market research companies and at 1&1 Internet SE (now 1&1 IONOS SE), the leading European Webhosting and Cloud Applications company. Prior to that, Christian built up extensive digital and customer-centric expertise in several functions at Software AG, Amazon and Nestlé.
“We are very pleased to welcome Christian as the new CFO of Innoplexus. Christian has an excellent entrepreneurial mindset, inherited from a strong family business background. His very successful track record in value creation includes leading high growth companies in the tech and data sector to the next level of development. Christian’s Finance expertise will be instrumental for Innoplexus in the dialogue with our investment community, fundraising, and capital market transactions,” said Dr. Gunjan Bhardwaj, Founder and CEO of Innoplexus.
Christian holds degrees from ESADE Business School in Barcelona, Spain, and the Community of European Management Schools (CEMS) in cooperation with the University of St. Gallen, Switzerland.
On January 1, 2020, Dr. Katharina Schreeb commenced the newly created position as Chief Medical
Officer (CMO) of Innoplexus AG. The 53-year-old medical doctor is an internationally recognized expert in the pharmaceutical and biotechnology industry with more than 20 years of clinical and scientific experience. Prior to Innoplexus, Schreeb was Head of Medical Affairs at BioNtech SE, one of the fastest-growing biotech companies worldwide. Previously, she held various management positions at Boehringer Ingelheim, Eli Lilly, and Pharmacia and was responsible for numerous successful launches of pharmaceutical products in the international market, especially in the field of oncology.
“We are extremely pleased that renowned expert Dr. Katharina Schreeb joins our company. Katharina has comprehensive expertise in the pharmaceutical and biotechnology industry with an excellent professional reputation. With her outstanding clinical and scientific experience, she will further drive the development of our services for the international life science market”, said Gunjan Bhardwaj, founder and CEO of Innoplexus AG. Katharina holds an MBA from the City University of Bellevue, WA, and worked at the University of Göttingen at the department of Clinical Pharmacology. She has published more than 25 scientific articles in international specialist publications.
Innoplexus AG
Innoplexus is a leading global AI-champion with over 300 employees and 100+ patent applications including 12 grants in artificial intelligence, machine learning, and blockchain technologies. Innoplexus applies its proprietary tech stack in all stages of the drug development value chain via smart Data as a Service (DaaS) and Continuous Analytics as a Service (CAaS) solutions. Generating real-time insights from hundreds of terabytes of structured and unstructured private and public data, Innoplexus helps organizations move towards continuous decision-making. Founded in 2015, Innoplexus AG is headquartered in Eschborn, Germany, with offices in Pune, India, and Iselin, and San Francisco United States.
Featured News
Partex NV announces collaboration with Althea DRF Lifesciences to provide
Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF…
Innovative AI technology in oncology: Partex Group presents results from
During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the…
Partex NV Forges Collaboration with Sanofi in AI-Based Dossier Enrichment
Frankfurt, Germany; 14 March 2024 Partex Group, a pioneer in AI-driven drug discovery, today announces a collaboration with global pharmaceutical…
Innoplexus and AIO Studien gGmbH are jointly announcing the start
January 02, 2024 – Innoplexus and Amrit AG, members of the Partex NV Group, providers of innovative technology for health…
Strategic partnership announcement: Innoplexus holding company Partex NV is pleased
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…
AI supports targeted therapy recommendations fortumor diseases – BMBF funds
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary…
Innoplexus and Innovatrix capital partner to bring about new risk-transfer
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning…
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30,…
Parexel and Innoplexus Unveil Single Source of COVID-19 Information for
COVID-19 Clearinghouse enables direct access to latest COVID-19 datasets, publications, research and clinical trials BOSTON and DURHAM, N.C. and ESCHBORN, Germany,…
New app for cancer patients
Das Eschborner Unternehmen Innoplexus hat eine neue App namens „Curia“ für Krebspatienten veröffentlicht. Mit dem Computerprogramm, das sich unentgeltlich herunterladen…